^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herzuma (trastuzumab-pkrb) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
(Approved for Gastroesophageal Junction Adenocarcinoma)
New
Excerpt:
Herzuma in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Source:
Title:
Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer
Published date:
02/01/2022
Excerpt:
The findings of this retrospective study demonstrated that biosimilar trastuzumab (CT-P6) is as efficacious as reference trastuzumab in terms of response rates, PFS and OS with comparable toxicity in patients with HER2-positive AGC.
DOI:
10.1097/COC.0000000000000887
